#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dermatitis atopic Breast cancer metastatic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    B-cell small lymphocytic lymphoma refractory Leiomyosarcoma recurrent Emphysema Warm autoimmune haemolytic anaemia Neuroendocrine tumour of the lung Breast angiosarcoma Spinal cord injury cervical Familial hypertriglyceridaemia Arginase deficiency Factor VIII deficiency Hereditary ataxia Nephrotic syndrome Ehlers-Danlos syndrome Head and neck cancer Splenic marginal zone lymphoma More trials…

    Learn about Rare Diseases

    Choroid melanoma – Diagnostics Hepatoblastoma Adrenogenital syndrome – Life with Disease Aicardi-Goutieres syndrome – Basic Information Encephalitis autoimmune Primary hyperoxaluria – Diagnostics Hereditary optic atrophy Gaucher’s disease type III – Diagnostics Cystic fibrosis – Life with Disease Basal cell naevus syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Caffeine Gemcitabine Hydrochloride Dolutegravir Peboctocogene Camaparvovec Magnesium Stearate Calcium Varegacestat Psma-11 Bromocriptine Sodium Phenylbutyrate Dazostinag Marstacimab Ioflupane (123I) Ly3541860 Pyrazinamide Verapamil Atl001 Emedastine Solifenacin Succinate Hydroxycarbamide More therapies…

    Learn about Your Condition

    Exudative retinopathy Pyoderma gangrenosum Pancreatitis chronic Diabetic nephropathy Persistent depressive disorder Stem cell transplant Multiple sclerosis relapse Chorioretinitis Complicated appendicitis Renal cell carcinoma stage IV Arrhythmia Embolism venous Intestinal ischaemia Biotinidase deficiency Inflammatory bowel disease More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uncategorized

  • Safety, CNS penetration and target engagement of Mirivadelgat in participants with Parkinson’s disease

    Not yet recruiting

    2 1
    Investigated Diseases:
    • Parkinson’s disease
    Norway

  • Evaluation of V-Cu64 versus V-Ga68 PET-CT imaging in adults with diagnosed or suspected neuroendocrine tumors

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Neuroendocrine tumour
    Investigated Drugs:
    • Copper (64Cu) Chloride
    • Edotreotide
    • Gallium (68Ga) Chloride
    Poland

  • Tranexamic Acid versus Placebo for Reducing Infection after Mid‑and Hind‑Foot Arthrodesis in Adults with Deformity or Osteoarthritis

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Osteoarthritis
    Investigated Drugs:
    • Tranexamic Acid
    • Sodium Chloride
    Finland

  • Long‑Term Safety and Tolerability of KarXT in Adolescents with Schizophrenia and of KarXT + KarX‑EC in Children and Adolescents with Autism‑Related Irritability

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Autism spectrum disorder
    • Schizophrenia
    Investigated Drugs:
    • Trospium Chloride
    • Xanomeline Tartrate
    Romania

  • Effect of Continuing vs Stopping Dapagliflozin (with other drug combinations) on 30‑Day Cardiovascular Outcomes in Heart Failure Patients Undergoing Cardiac Surgery

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Cardiac failure
    Investigated Drugs:
    • Metformin Hydrochloride
    • Empagliflozin
    • Dapagliflozin
    France

  • Safety and efficacy of autologous CD34+ cells transduced with a vector encoding human NCF1 in children and adults with p47‑deficient chronic granulomatous disease

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Chronic granulomatous disease
    Germany Spain
Previous Page
1 … 702 703 704 705 706 … 1,657
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!